The aim of a study was to identify risk factors for the development of statin-associated diabetes mellitus ( DM ).
The study was conducted in two phases. Phase one involved high-throughput in silico processing of a large amount of biomedical data to identify risk factors for the development of statin-associated diabetes mellitus. In phase two, the most prominent risk factor identified was confirmed in an observational cohort study at Clalit, the largest health-care organization in Israel.
A total of 39,263 statin nonusers were matched by propensity score to 20,334 highly compliant statin initiators in 2004-2005 and followed until the end of 2010. Within 59,597 statin users and nonusers in a multivariable model, hypothyroidism and subclinical hypothyroidism carried an increased risk for diabetes mellitus ( RR=1.53 [ 95% CI 1.31-1.79 ] and 1.75 [ 1.40-2.18 ], respectively ).
Hypothyroidism increased diabetes mellitus risk irrespective of statin treatment ( RR=2.06 [ 1.42-2.99 ] and 1.66 [ 1.05-2.64 ] in statin users and nonusers, respectively ).
Subclinical hypothyroidism risk for diabetes mellitus was prominent only upon statin use ( RR=1.94 [ 1.13-3.34 ] and 1.20 [ 0.52-2.75 ] in statin users and nonusers, respectively ).
Patients with hypothyroidism treated with thyroid hormone replacement therapy were not at increased risk for diabetes mellitus.
In conclusion, hypothyroidism is a risk factor for diabetes mellitus. Subclinical hypothyroidism-associated risk for diabetes mellitus is prominent only upon statin use.
Identifying and treating hypothyroidism and subclinical hypothyroidism might reduce diabetes mellitus risk. ( Xagena )
Gronich N et al, Diabetes Care 2015; Epub ahead of print